Gencurix Inc Asset Resilience Ratio
Gencurix Inc asset resilience ratio. Gencurix Inc (229000) has an Asset Resilience Ratio of 4.01% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Gencurix Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Gencurix Inc (2016–2024)
Asset resilience ratio of Gencurix Inc from 2016 to 2024. This chart shows how Gencurix Inc's Asset Resilience Ratio has changed over time. Read debt load of Gencurix Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Gencurix Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Gencurix Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩1.08 Billion | 4.01% |
| Total Liquid Assets | ₩1.08 Billion | 4.01% |
Asset Resilience Insights
- Limited Liquidity: Gencurix Inc maintains only 4.01% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Gencurix Inc Industry Peers by Asset Resilience Ratio
Compare Gencurix Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Voxel S.A.
WAR:VOX |
Diagnostics & Research | 0.32% |
|
Leveljump Healthcare Corp
V:JUMP |
Diagnostics & Research | 32.45% |
|
Prodia Widyahusada Tbk PT
JK:PRDA |
Diagnostics & Research | 7.82% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Gencurix Inc Asset Resilience Ratio by Year (2016–2024)
Gencurix Inc asset resilience ratio by year from 2016 to 2024. The table below shows the annual Asset Resilience Ratio data for Gencurix Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 15.11% | ₩4.54 Billion ≈ $3.08 Million |
₩30.04 Billion ≈ $20.36 Million |
-18.54pp |
| 2023-12-31 | 33.65% | ₩11.27 Billion ≈ $7.64 Million |
₩33.50 Billion ≈ $22.70 Million |
+17.65pp |
| 2022-12-31 | 16.01% | ₩5.96 Billion ≈ $4.04 Million |
₩37.24 Billion ≈ $25.24 Million |
-23.72pp |
| 2021-12-31 | 39.73% | ₩21.96 Billion ≈ $14.88 Million |
₩55.29 Billion ≈ $37.47 Million |
+30.93pp |
| 2020-12-31 | 8.80% | ₩5.63 Billion ≈ $3.81 Million |
₩63.98 Billion ≈ $43.36 Million |
-16.06pp |
| 2019-12-31 | 24.85% | ₩593.34 Million ≈ $402.10K |
₩2.39 Billion ≈ $1.62 Million |
-46.40pp |
| 2018-12-31 | 71.25% | ₩7.23 Billion ≈ $4.90 Million |
₩10.14 Billion ≈ $6.87 Million |
+9.81pp |
| 2017-12-31 | 61.44% | ₩4.52 Billion ≈ $3.07 Million |
₩7.36 Billion ≈ $4.99 Million |
-7.41pp |
| 2016-12-31 | 68.85% | ₩6.36 Billion ≈ $4.31 Million |
₩9.23 Billion ≈ $6.26 Million |
-- |
About Gencurix Inc
Gencurix Inc. provides diagnostic solutions in South Korea. Its products include GenesWell BCT, a multigene diagnostic test for breast cancer; Droplex, a genetic test based on digital PCR platform; eDX, an early diagnosis for cancer with liquid biopsy; GenePro SARS-CoV-2 Test kit; GenoCTC, a circulating tumor cell isolator; and GenePro LAMP Cycler, a portable device for infectious disease detecti… Read more